Skip to main content

ERRATUM article

Front. Pharmacol., 20 September 2022
Sec. Ethnopharmacology

Erratum: Xiongshao Zhitong recipe attenuates nitroglycerin-induced migraine-like behaviors via the inhibition of inflammation mediated by nitric oxide synthase

An Erratum on
Xiongshao Zhitong recipe attenuates nitroglycerin-induced migraine-like behaviors via the inhibition of inflammation mediated

by Yang S, Chen C, Liu X, Kang Q, Ma Q, Li P, Hu Y, Li J, Gao J, Wang T and Wang W (2022). Front. Pharmacol. 13:920201. doi: 10.3389/fphar.2022.920201

Due to a production error the incorrect versions of Figures 1, 7 were published. The corrected Figures 1, 7 appear below.

FIGURE 1
www.frontiersin.org

FIGURE 1. Identification results of themain chemical components of XZR by UHPLC-LTQ-Orbitrap MS. (A) Total ion flow diagram of XZR in anion mode (details of Nos. 1–35 are listed in Supplementary Table S1). (B) Total ion flow diagram of XZR in the positive ion mode (details of Nos. 1–27 are listed in Supplementary Table S2). (C) Identification of the main components in XZR. XZR, Xiongshao Zhitong Recipe.

FIGURE 7
www.frontiersin.org

FIGURE 7. XZR inhibited inflammation via the NF-κB signaling pathway. (A) Representative Western blot images of IKKβ, IκBα, and NF-κB expression in the TNC. (B) Relative expression of IKKβ in the TNC. (C) Relative expression of IκBα in the TNC. (D) Relative expression of NF-κB in the TNC. (E) Representative Western blot images of IKKβ, IκBα, and NF-κB expression in the midbrain. (F) Relative expression of IKKβ in the midbrain. (G) Relative expression of IκBα in the midbrain. (H) Relative expression of NF-κB in the midbrain. Data are presented as the mean ± standard deviation, n = 3–5. ##p < 0.01 versus the control group, *p < 0.05, **p < 0.01 versus the NTG group. XZR, Xiongshao Zhitong Recipe; NTG, nitroglycerin.

The publisher apologizes for this mistake. The original version of this article has been updated.

Citation: Frontiers Production Office (2022) Erratum: Xiongshao Zhitong recipe attenuates nitroglycerin-induced migraine-like behaviors via the inhibition of inflammation mediated by nitric oxide synthase. Front. Pharmacol. 13:1021407. doi: 10.3389/fphar.2022.1021407

Received: 17 August 2022; Accepted: 17 August 2022;
Published: 20 September 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.